ES2241571T3
(es)
*
|
1999-01-15 |
2005-11-01 |
Altana Pharma Ag |
N-oxidos de fenantrinida con actividad inhividora de pde-iv.
|
CA2359404A1
(en)
|
1999-01-15 |
2000-07-20 |
Beate Gutterer |
Phenanthridine-n-oxides with pde-iv inhibiting activity
|
JP5038568B2
(ja)
|
1999-08-21 |
2012-10-03 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
協力剤の組合せ物
|
US6953774B2
(en)
|
2000-08-11 |
2005-10-11 |
Applied Research Systems Ars Holding N.V. |
Methods of inducing ovulation
|
CN1518542A
(zh)
|
2001-01-31 |
2004-08-04 |
�Ʒ� |
用作pde4同工酶的抑制剂的烟酰胺联芳基衍生物
|
US7250518B2
(en)
|
2001-01-31 |
2007-07-31 |
Pfizer Inc. |
Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
|
NZ526531A
(en)
|
2001-01-31 |
2005-02-25 |
Pfizer Prod Inc |
Ether derivatives useful as inhibitors of phosphodiesterase type IV (PDE4) isozymes
|
MXPA03006886A
(es)
|
2001-01-31 |
2003-11-13 |
Pfizer Prod Inc |
Derivados amida de acido tiazolilico, oxazolilico, pirrolilico e imidazolilico utiles como inhibidores de las isozimas pde4.
|
ES2427930T3
(es)
*
|
2001-05-23 |
2013-11-04 |
Mitsubishi Tanabe Pharma Corporation |
Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
|
DE60233884D1
(de)
|
2001-10-16 |
2009-11-12 |
Memory Pharmaceutical Corp |
4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
|
MY130622A
(en)
|
2001-11-05 |
2007-07-31 |
Novartis Ag |
Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
|
BRPI0117198B1
(pt)
|
2001-12-14 |
2018-03-13 |
Merck Serono S.A. |
Usos de composição compreendendo um inibidor seletivo de uma isoforma 4 de fosfodiesterase
|
CN100513397C
(zh)
|
2002-11-19 |
2009-07-15 |
记忆药物公司 |
磷酸二酯酶4抑制剂
|
GB0229281D0
(en)
*
|
2002-12-16 |
2003-01-22 |
Novartis Ag |
Organic compounds
|
CA2522631A1
(en)
*
|
2003-04-16 |
2004-11-04 |
Memory Pharmaceuticals Corporation |
4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
|
EP1631568A1
(en)
*
|
2003-04-18 |
2006-03-08 |
Memory Pharmaceuticals Corporation |
Pyrazole derivatives as phosphodiesterase 4 inhibitors
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
MY141255A
(en)
|
2003-12-11 |
2010-03-31 |
Memory Pharm Corp |
Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
WO2006073413A1
(en)
*
|
2004-02-20 |
2006-07-13 |
The Board Of Trustees Of The University Of Illinois |
Blood pressure reduction in salt-sensitive
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
WO2006002284A1
(en)
*
|
2004-06-22 |
2006-01-05 |
Rigel Pharmaceuticals, Inc. |
Ubiquitin ligase inhibitors
|
JP2008513371A
(ja)
*
|
2004-09-14 |
2008-05-01 |
ノバルティス アクチエンゲゼルシャフト |
8−ハロ−1,7−ナフタピリジン誘導体と有機ボロン酸誘導体の反応による6,8−置換−1,7−ナフタピリジン誘導体の製造方法および該方法の中間体
|
US7432266B2
(en)
*
|
2004-10-15 |
2008-10-07 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
CN101166737A
(zh)
*
|
2004-10-20 |
2008-04-23 |
记忆药物公司 |
磷酸二酯酶4抑制剂
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
JP2006241111A
(ja)
*
|
2005-03-04 |
2006-09-14 |
Univ Nihon |
新規ベンゾフロキサン及びその合成法
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
EP1928437A2
(en)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
EP1957530A2
(en)
|
2005-10-21 |
2008-08-20 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
US20080280892A1
(en)
*
|
2005-10-21 |
2008-11-13 |
Nathalie Cailleau |
Compounds
|
CA2625153A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
AU2006308889A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
GABA receptor mediated modulation of neurogenesis
|
US20070185153A1
(en)
|
2005-12-22 |
2007-08-09 |
Nathalie Cailleau |
Compounds
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
GB0601951D0
(en)
*
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
DK2013211T3
(da)
|
2006-04-21 |
2012-07-02 |
Novartis Ag |
Purinderivater til anvendelse som adenosin-A2A-receptoragonister
|
EP2382975A3
(en)
|
2006-05-09 |
2012-02-29 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
WO2007134077A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
MX2009002496A
(es)
|
2006-09-08 |
2009-07-10 |
Braincells Inc |
Combinaciones que contienen un derivado de 4-acilaminopiridina.
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
DE602007013441D1
(de)
|
2006-09-29 |
2011-05-05 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
CN101522682A
(zh)
|
2006-10-30 |
2009-09-02 |
诺瓦提斯公司 |
作为抗炎剂的杂环化合物
|
DK2104535T3
(da)
|
2007-01-10 |
2011-04-04 |
Irm Llc |
Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
|
CA2685546A1
(en)
|
2007-05-07 |
2008-11-13 |
Novartis Ag |
Organic compounds
|
NZ585789A
(en)
|
2007-12-10 |
2012-03-30 |
Novartis Ag |
Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
|
PL2231642T3
(pl)
|
2008-01-11 |
2014-04-30 |
Novartis Ag |
Pirymidyny jako inhibitory kinazy
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
MX2010013675A
(es)
|
2008-06-10 |
2011-02-15 |
Novartis Ag |
Derivados de pirazina como bloqueadores del canal de sodio epitelial.
|
WO2010088335A1
(en)
|
2009-01-29 |
2010-08-05 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
EP2464649A1
(en)
|
2009-08-12 |
2012-06-20 |
Novartis AG |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
NZ598220A
(en)
|
2009-08-17 |
2014-02-28 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
EP2490687A1
(en)
|
2009-10-22 |
2012-08-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
HUE031710T2
(en)
|
2010-07-14 |
2017-07-28 |
Novartis Ag |
IP receptor agonist heterocyclic compounds
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
MA34969B1
(fr)
|
2011-02-25 |
2014-03-01 |
Irm Llc |
Composes et compositions en tant qu inibiteurs de trk
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
BR112014006223A8
(pt)
|
2011-09-15 |
2018-01-09 |
Novartis Ag |
3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
|
EP2755652B1
(en)
|
2011-09-16 |
2021-06-02 |
Novartis AG |
N-substituted heterocyclyl carboxamides
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
US9034879B2
(en)
|
2011-09-16 |
2015-05-19 |
Novartis Ag |
Heterocyclic compounds for the treatment of CF
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
JP6130391B2
(ja)
|
2011-11-23 |
2017-05-17 |
インテリカイン, エルエルシー |
Mtor阻害剤を使用する強化された治療レジメン
|
EP2804603A1
(en)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
WO2013105057A1
(en)
|
2012-01-13 |
2013-07-18 |
Novartis Ag |
Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
MX371119B
(es)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
|
JP5907006B2
(ja)
*
|
2012-09-04 |
2016-04-20 |
エヌ・イーケムキャット株式会社 |
ビフェニル化合物の合成方法
|
JP5907005B2
(ja)
*
|
2012-09-04 |
2016-04-20 |
エヌ・イーケムキャット株式会社 |
ビフェニル化合物の合成方法
|
WO2014125413A1
(en)
|
2013-02-13 |
2014-08-21 |
Novartis Ag |
Ip receptor agonist heterocyclic compounds
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
JP2016512835A
(ja)
|
2013-03-15 |
2016-05-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせ及びそれらの使用
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
JP6404944B2
(ja)
|
2014-04-24 |
2018-10-17 |
ノバルティス アーゲー |
ホスファチジルイノシトール3−キナーゼ阻害薬としてのピラジン誘導体
|
EA032075B1
(ru)
|
2014-04-24 |
2019-04-30 |
Новартис Аг |
Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
|
ES2761569T3
(es)
|
2014-04-24 |
2020-05-20 |
Novartis Ag |
Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas
|
US9741941B2
(en)
|
2014-04-29 |
2017-08-22 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
JP6526789B2
(ja)
|
2014-07-31 |
2019-06-05 |
ノバルティス アーゲー |
組み合わせ療法
|
AU2020290094B2
(en)
|
2019-06-10 |
2024-01-18 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
|
AR119819A1
(es)
|
2019-08-28 |
2022-01-12 |
Novartis Ag |
Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|